News >

Expert Makes Case for Frontline Targeted Therapy in Select MCL Subtypes

Brandon Scalea
Published: Friday, Jun 21, 2019

blood cellsPatients with mantle cell lymphoma (MCL), particularly those with p53 mutations and those who have a poor prognosis, should be treated with targeted therapy upfront, said Ezzat Elhassadi, MD.

In a study presented at the 2019 European Hematology Association Congress, 29 patients with MCL were observed over a 10-year period. Researchers found that patients harboring p53 mutations correlated directly with overall survival (OS). Median OS in the 20% of patients with p53-mutated disease was approximately 4 years; OS had not been reached in the wild-type subset (P = .007).

“From these data, we are advocating about using targeted therapy upfront in MCL—especially in patients who are not fit for the standard of care, including autologous stem cell transplant (ASCT),” explained Elhassadi, a consultant hematologist at University Hospital Waterford. “Potentially, if we use our targeted therapy early in the disease course upfront, there are data supporting that the response rates will be better.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x